

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850

Status	RECRUITING
Phase	Phase 3
Sponsor	Metsera, a wholly owned subsidiary of Pfizer
Enrollment	3,500 participants

Key Eligibility Criteria

Inclusion (1)

- BMI \geq 30 kg/m² or BMI \geq 27.0 kg/m² to $<$ 30.0 kg/m² and presence of at least 1 of the following weight-related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

Exclusion (4)

- Have any form of diabetes
- Have a self-reported body weight change $>$ 5 kg (11 pounds) within 3 months prior to Screening
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease

Locations (5 total)

Research Site 97301-001007, Riverside, California, United States
Research Site 97301-001070, Torrance, California, United States
Research Site 97301-001077, Englewood, Colorado, United States
... and 2 more locations